- WuXi Biologics and Earendil Labs have signed a strategic collaboration agreement to develop and manufacture bispecific and multispecific antibodies and antibody–drug conjugate (ADC) candidates.
- The partnership will combine Earendil Labs’ AI-driven biologics research with WuXi Biologics’ end-to-end development and manufacturing capabilities.
WuXi Biologics has entered into a strategic collaboration agreement with Earendil Labs to support the development and manufacturing of multiple bispecific and multispecific antibodies and antibody–drug conjugate (ADC) candidates in Earendil’s therapeutic pipeline. The programs target autoimmune disease, cancer, and other diseases.
Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services. These include cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. The collaboration is intended to support global clinical development across Earendil Labs’ programs while aiming to accelerate regulatory timelines and strengthen CMC execution.
WuXi Biologics stated that it has developed capabilities in complex biologics, including bispecific and multispecific antibodies and ADCs. By 2025, a total of 945 projects were advancing on the company’s integrated CRDMO platform, with bispecific and multispecific antibodies representing one of the fastest-growing categories.
“We are delighted to enter this strategic collaboration with Earendil Labs, a company distinguished by its strong scientific leadership and innovative approach to advancing next-generation immunotherapies.”
Dr. Chris Chen, CEO of WuXi Biologics
The companies said the collaboration will integrate Earendil Labs’ AI-driven protein engineering capabilities with WuXi Biologics’ biologics development and contract manufacturing infrastructure to support the advancement of Earendil’s pipeline programs toward clinical development.
